Comparison of Imaging Quality Between Spectral Photon Counting Computed Tomography (SPCCT) and Dual Energy Computed Tomography (DECT)
Hospices Civils de Lyon
339 participants
Jan 29, 2021
INTERVENTIONAL
Conditions
Summary
This pilot study wants to determine to which extent SPCCT allows obtaining images with improved quality and diagnostic confidence when compared to standard Dual Energy CT (DECT), both with and without contrast agent injection. Depending on the anatomical structures/organs to be visualized during CT examinations, different scanning protocols are performed with quite variable ionizing radiation doses. Therefore, in order to obtain the most extensive and representative results of the improvement in image quality between SPCCT and DECT that will be performed CT imaging on several body regions and structures, including diabetic foot, diabetic calcium coronary scoring, adrenal glands, coronary arteries, lung parenchyma, kidney stones, inner ear, brain and joints, earl/temporal bone, colorectal carcinosis.
Eligibility
Inclusion Criteria17
- Patients presenting following one of following medical conditions:
- Asymptomatic type 1 or 2 diabetes as regard to cardiovascular risks
- Diabetic foot ulcer
- Adrenal glands lesions: Adrenal incidentaloma or hyperaldosteronism or macroadenoma
- Urinary stone(s)
- Known Coronary artery disease: Stent imaging or control of calcified plaques
- Diffuse Interstitial Lung Diseases: Idiopathic Pulmonary Fibrosis, Hypersensitivity Pneumonitis, Ground Glass Opacification, Chronic Thromboembolic Pulmonary Hypertension
- Conductive hearing loss
- Brain stroke (late or post thrombectomy)
- Intracranial arteriovenous malformation treated with coils or Onyx
- Joints diseases in haemophilia
- Ear/temporal bone
- Colorectal carcinosis
- Dissection aortique de type A opérée ou de type B non opérée, hématome intramural
- Patient has accepted to participate to the study and has signed the written consent;
- Pre-menopausal women only: Negative urinary pregnancy test on the day of imaging before the administration of study drug;
- Patient is affiliated to the French social security
Exclusion Criteria8
- Contraindication to the use of iodine containing contrast media (including subjects with suspicion for/or known to have NSF) (if injection);
- History of severe allergic or anaphylactic reaction to any allergen including drugs and contrast agents (as judged by the investigator, taking into account the intensity of the event);
- History of delayed major or delayed cutaneous reaction to Iomeron injection
- Estimated Glomerular Filtration Rate (eGFR) value \< 30 mL/min/1.73 m2 derived from a serum creatinine result within 1 month before the imaging for examinations with contrast agent.
- Any subject on hemodialysis or peritoneal dialysis;
- Suspected clinical instability or unpredictability of the clinical course during the study period (e.g. due to previous surgery);
- Pregnant or nursing (including pumping for storage and feeding);
- Patient under guardianship, curatorship or safeguard of justice.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
For the dual-layer spectral CT scanner (IQon®, Philips, Amsterdam, The Netherlands), the following parameters will be used for the acquisition: * Tube potential 120 kVp; * Tube current time product of 150 mAs; * Gantry revolution time 0.33 s; * Automatic exposure control (angular and longitudinal) combined xyz-axis; * Beam collimation geometry 64 x 0.625 mm - scan field-of-view - 22 cm;
The SPCCT scanner is a prototype spectral photon-counting computed tomography system derived from a modified clinical CT system with a field-of-view (FOV) of 168 mm in-plane, and a z-coverage of 20 mm. It is equipped with energy-sensitive photon-counting detectors relying on the direct conversion high band gap semiconductor of cadmium zinc telluride (CZT). The electronics comprises 5 rate counters with 5 different configurable energy thresholds. The SPCCT scanner has the following parameters: * Base platform : iCT scanner * Tube Voltage (kVp) : 120, capability for imaging at 80 and 100 kVp * Tube current (mA) : 10 - 300 * Spatial Resolution : \> 30 lp/cm, ≤ 250 µm * Z-coverage isocenter (mm) : 20 mm * FOV (mm) : 500 * Minimum rotation time : 0.33 s/rotation * Acquisition modes : Axial, Helical, Step \& Shoot
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT04328181